Shares of NuScale Power Corporation dropped 5.50% on Wednesday. The decline pulled back nearly all of the previous session’s AI-driven increase. The move also underscored a significant valuation challenge: accelerated engineering has not yet translated into customer revenue.
| Company | Close | Aug. 26 | Revenue signal | Risk profile |
|---|---|---|---|---|
| NuScale Power | $9.27 | −5.50% | $75K Q2 | Pre-commercial |
| Oklo | $41.60 | −6.03% | $1.21M TTM | Early revenue |
| NANO Nuclear | $18.50 | −3.85% | $214K TTM | Development |
| BWX Technologies | $153.16 | +2.29% | $3.51B TTM | Profitable supplier |
The 80% retrieval-time claim targets engineering productivity and schedule risk. It does not yet quantify lower R&D spending, faster licensing or contract revenue. The balance sheet extends the runway, but binding customer commitments remain the decisive valuation bridge.
Risks: Proof-of-concept results may not scale. Nuclear licensing, customer financing, manufacturing capacity, partner execution and dilution can overwhelm workflow savings.
Market close · August 25, 2026 · 16:00 EDT
Ontario named uranium as possible trade leverage. Oklo rallied, though no cutoff or new Oklo contract was announced.
The session's added value equaled 6.7× Oklo's $126.9M first-half capital spending. That is a sentiment move, not realized cash flow.
| Metric | Amount |
|---|---|
| Cash + marketable securities | $3.01B |
| H1 ATM equity proceeds | $1.85B |
| H1 operating cash use | $65.5M |
| H1 capital spending | $126.9M |
| 2026 operating cash-use guide | $120–150M |
| 2026 PP&E guide | $400–500M |
Balance-sheet figures through June 30, 2026. Source: Oklo Form 10-Q and Q2 call.
| Measure | Target / view |
|---|---|
| Consensus | Buy · 15/9/1 |
| Average target | $79.88 · +80% |
| Median target | $81.50 · +84% |
| Truist | Hold · $51 |
| H.C. Wainwright | Buy · $90 |
| Canaccord | Buy · $100 |
Latest compiled targets available August 25; recent firm calls dated August 10.
Policy riskHALEU accessGroves executionAurora scheduleEquity dilution
Oklo has enough liquidity to fund near-term work, but its $8.23B value still depends on regulatory progress and future commercial deployment. The uranium threat supports the strategic case for domestic fuel. It does not itself create revenue. A reversal in trade rhetoric could therefore unwind part of Tuesday's gain.
Sources: Yahoo Finance close and volume; Oklo Q2 2026 Form 10-Q; Oklo Groves first-criticality release; Reuters and AP trade reporting; S&P Global analyst compilation. All market figures as of August 25, 2026, 16:00 EDT.
The balance sheet lowers financing pressure. It does not remove licensing, fuel-supply or commercialization risk.
| Firm | View | Target | Upside |
|---|---|---|---|
| Alliance Global | Buy | $46 | 144% |
| Truist | Hold | $22 | 16.7% |
| Benchmark | Buy | $45 | 138.7% |
| Roth/MKM | Buy | $45 | 138.7% |
| 7-analyst average | Buy | $40.83 | 116.6% |
Cash-rich, pre-power and priced for execution
Oklo bounced Friday after a volatile week, but no fresh company filing explained the move. Investors balanced the Groves reactor milestone and deep liquidity against a long commercial-power timeline, higher planned spending and a reduced Texas Capital target.
